drugset / Trial / NCT02167139

A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy

NCT02167139

Phase 3 Completed 544 enrolled Samsung Bioepis Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomised, double-blind, parallel group, multicentre clinical study to evaluate the efficacy, safety, tolerability, pharmacokinetics and immunogenicity of SB5 compared to Humira® in subjects with moderate to severe RA despite MTX therapy.

Timeline

Start
2014-05
Primary completion
2015-04
Completion
2015-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Adalimumab Monoclonal antibody 40 mg Subcutaneous

Indications